June 30, 2020 / 12:31 PM / 4 days ago

BRIEF-Revance Announces Positive Results In Two Phase 2A Studies For Treatment Of Forehead Lines And Crow’s Feet

June 30 (Reuters) - Revance Therapeutics Inc:

* REVANCE ANNOUNCES POSITIVE RESULTS IN TWO PHASE 2A STUDIES OF DAXIBOTULINUMTOXINA FOR INJECTION FOR THE TREATMENT OF FOREHEAD LINES AND CROW’S FEET, RESPECTIVELY

* REVANCE THERAPEUTICS INC - DAXIBOTULINUMTOXINA FOR INJECTION WAS WELL TOLERATED ACROSS ALL DOSES IN BOTH INDICATIONS

* REVANCE ANNOUNCES POSITIVE RESULTS IN TWO PHASE 2A STUDIES OF DAXIBOTULINUMTOXINA FOR INJECTION FOR TREATMENT OF FOREHEAD LINES AND CROW’S FEET, RESPECTIVELY

* REVANCE THERAPEUTICS INC - AT LEAST ONE DOSE IN EACH STUDY DEMONSTRATED A MEASURABLE TREATMENT EFFECT IN 100% OF SUBJECTS AT 4 WEEKS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below